Molecular Templates (Molecular Templates) EPS (Basic) : $-1.63 (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Molecular Templates EPS (Basic)?

Molecular Templates's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.63.

Molecular Templates's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.63.

Molecular Templates's EPS without NRI for the three months ended in Dec. 2023 was $-1.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -2.48.

During the past 3 years, the average EPS without NRI Growth Rate was 56.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Molecular Templates's highest 3-Year average EPS without NRI Growth Rate was 65.50% per year. The lowest was -168.70% per year. And the median was 30.30% per year.

Molecular Templates EPS (Basic) Historical Data

The historical data trend for Molecular Templates's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates EPS (Basic) Chart

Molecular Templates Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-27.90

-33.00

-22.50

-24.69

-1.80

Molecular Templates Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-5.85	2.85	-2.85	-0.82	-0.81

Molecular Templates EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Molecular Templates's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.124	-	0)	/	4.501
	=	-1.80

Molecular Templates's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.948	-	0)	/	5.384
	=	-0.73

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

Molecular Templates (NAS:MTEM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Molecular Templates EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Molecular Templates's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Templates (Molecular Templates) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729

Website

https://www.mtem.com

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.

Executives

Maurizio Voi	officer: Chief Medical Officer	4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan	officer: CFO & Treasurer	C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande	director, 10 percent owner	201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc	10 percent owner	FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim	officer: See Remarks	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright	10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms	10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch	director, 10 percent owner	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p.	10 percent owner	800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein	director	C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019